NICE Recommends Eli Lilly’s Breast Cancer Treatment for NHS Use
The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service (NHS) offer Eli Lilly’s Verzenios (abemaciclib) plus hormonal therapy fulvestrant as a treatment for breast cancer.
NICE specially recommended the treatment for women with hormone receptor-positive, HER2-negative breast cancer that has spread to other parts of the body.
The UK list price for Verzenios is approximately $4,100 per 28-day cycle. NICE previously rejected Verzenios because of the cost but has now accepted a revised pricing structure from the company for NHS use. The newly agreed price was not disclosed.